The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions…
Trial also will test pausing immunosuppressive medication to improve antibody response. The National Institutes of Health has begun a clinical trial to assess the antibody…
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in…
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic…
Recently, media reports and pre-print scientific papers on SARS-CoV-2 variants have discussed various genetic mutations in the virus that have occurred. SARS-CoV-2 is the virus…
A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who have mild…
The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results…
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, announced that the fourth iteration of the Adaptive COVID-19…
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a study on October 13, 2020, designed to…
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir…
A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers. The trial is designed to…
A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine,…
NIAID-sponsored phase 1 trial tested mRNA vaccine An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19),…
More than 300 scientists and clinicians from the federal government, industry and academia published a report of their conclusions and recommendations on COVID-19 serology studies…
Study is a wake-up call for the potential of another such outbreak, as vaccination rates plummet during the COVID-19 pandemic. An analysis of the 2018-2019…
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New…
Study provided data for clinical testing to commence. A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from…
Study enrolling adults with mild to moderate COVID-19 in the United States. A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given…